Genomic determinants of response to cytotoxic chemotherapy.

Slides:

Advertisements

Similar presentations

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

Advertisements

A paradigm shift in the treatment of advanced lung cancer: survival and symptom benefits with Tarceva Tudor-Eliade Ciuleanu Cancer Institute Ion Chiricuta.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Volume 164, Issue 6, Pages (December 2000)

Copyright © 2010 American Medical Association. All rights reserved.

Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.

Amy M. Lin, Charles J. Ryan, Eric J. Small

Dose-escalation patient response.

Perspectives on Triple-Negative Breast Cancer

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Breast cancer. Breast cancer. A, antitumor activity of abemaciclib in a human xenograft model (T47D) of ER-positive, HER2-negative breast cancer. Athymic.

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,

Intrinsic and acquired trastuzumab resistance.

The Road to Quality Improvement in HER2-Positive Breast Cancer

Box and Whisker Plot of the Distribution of Perceived Stress Scores for TMD Controls and TMD CasesThe horizontal line within the box is the median value.

Response to Carfilzomib Therapy

Clinical responses in patients.

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.

X-bar and S control charts of LOS

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Box plot of acquisition times across the various study cohorts.

Dialyzer clearance of ampicillin/sulbactam in plasma of critically ill patients with AKI undergoing extended dialysis. Dialyzer clearance of ampicillin/sulbactam.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Cytotoxic activity of HER2-lytic hybrid peptide.

Expression analysis of IGFBP-3 using human whole-genome microarray.

T-cell phenotypes of cells harvested from the peripheral blood of patients undergoing chemotherapy. T-cell phenotypes of cells harvested from the peripheral.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Visualization of prescriptive algorithm: provider dashboard prototype.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

Nomogram depicting estimates of postprogression survival, including estimates of 6-, 12-, and 24-month OS according to prechemotherapy and postchemotherapy.

Temporal and spatial dissection of mutation spectra in esophageal adenocarcinoma samples. Temporal and spatial dissection of mutation spectra in esophageal.

Duration of treatment and intervals of radiographic and ctDNA response

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Location of the ER mutations and frequencies per cohort.

Change in FES uptake in the tumor during fulvestrant treatment.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

(A) Survival curves according to clinical response.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Serial CT scan images from patient with a partial response.

Survival, subsequent therapies, and response.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

In vivo shRNA screening in PDXs from 3 patients with melanoma.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

STK11/LKB1 comutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant LUAC. A, Objective response rate (RECISTv1.1)

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

Integrated analysis of gene expression and copy number alterations.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

Genomic determinants of response to cytotoxic chemotherapy. Genomic determinants of response to cytotoxic chemotherapy. A, Swimmer's plot showing months on first-line platinum-based therapy for 187 patients with metastatic, HER2− esophageal cancer. The annotation tracks on the left of the y-axis indicate the patient's best response to platinum and the estimated LST score. The color of individual bars indicates the current status of the patient on this line of treatment. B, Distribution of LST scores in patients who progressed on platinum treatment before 24 months compared with patients with prolonged response (≥24 months). Horizontal bars represent the median by group. CR, complete response; PR, partial response; SD, stable disease. Yelena Y. Janjigian et al. Cancer Discov 2018;8:49-58 ©2018 by American Association for Cancer Research